GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shandong Boan Biotechnology Co Ltd (HKSE:06955) » Definitions » Additional Paid-In Capital

Shandong Boan Biotechnology Co (HKSE:06955) Additional Paid-In Capital : HK$1,454.1 Mil(As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Shandong Boan Biotechnology Co Additional Paid-In Capital?


Shandong Boan Biotechnology Co's quarterly additional paid-in capital declined from Dec. 2022 (HK$1,484.6 Mil) to Jun. 2023 (HK$1,454.1 Mil) but then stayed the same from Jun. 2023 (HK$1,454.1 Mil) to Dec. 2023 (HK$1,454.1 Mil).

Shandong Boan Biotechnology Co's annual additional paid-in capital increased from Dec. 2021 (HK$0.0 Mil) to Dec. 2022 (HK$1,484.6 Mil) but then declined from Dec. 2022 (HK$1,484.6 Mil) to Dec. 2023 (HK$1,454.1 Mil).


Shandong Boan Biotechnology Co Additional Paid-In Capital Historical Data

The historical data trend for Shandong Boan Biotechnology Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Boan Biotechnology Co Additional Paid-In Capital Chart

Shandong Boan Biotechnology Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
- - 1,484.62 1,454.12

Shandong Boan Biotechnology Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Additional Paid-In Capital Get a 7-Day Free Trial - - 1,484.62 1,454.13 1,454.12

Shandong Boan Biotechnology Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Shandong Boan Biotechnology Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Shandong Boan Biotechnology Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Shandong Boan Biotechnology Co (HKSE:06955) Business Description

Traded in Other Exchanges
Address
No. 39 Keji Avenue, High-Tech Industrial Development Zone, Shandong Province, Yantai, CHN
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. The company is engaged in the development, manufacture, and commercialization of high-quality biologics in China and around the world. It focuses on areas such as oncology, metabolism, autoimmunity, and ophthalmology. Geographically company's revenue is generated from customers located in Mainland China.
Executives
Asiapharm Investments Ltd.
Ginkgo (ptc) Limited
Liu Dianbo
Luye Life Sciences Group Ltd
Luye Pharma Holdings Ltd.
Luye Pharma Hong Kong Limited
Luye Pharmaceutical International Co., Ltd.
Luye Pharmaceutical Investment Co., Ltd.
Nelumbo Investments Limited
Shorea Lbg
Luye Pharma Group Ltd.
Shan Dong Lv Ye Zhi Yao You Xian Gong Si
Yan Tai Lv Ye Yi Yao Kong Gu Ji Tuan You Xian Gong Si
Li Li 2201 Interest of corporation controlled by you

Shandong Boan Biotechnology Co (HKSE:06955) Headlines

No Headlines